Pfizer's Prostate Cancer Trial Hits Primary Endpoint, Bolstering Drug Portfolio

Pfizer's Phase 3 TALAPRO-3 trial shows the Talzenna-Xtandi combination significantly delays cancer progression in metastatic prostate cancer, unlocking a major new revenue opportunity.

A pivotal late-stage study combining two of Pfizer's oncology drugs has yielded positive results, potentially opening a significant new revenue stream for the pharmaceutical giant. On March 19, 2026, the company announced that its TALAPRO-3 Phase 3 trial successfully met its primary objective.

The investigation evaluated the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) in men with metastatic castration-sensitive prostate cancer (mCSPC). Data showed the regimen significantly extended radiographic progression-free survival (rPFS). The results surpassed the pre-defined statistical target, demonstrating a hazard ratio better than 0.63.

Consistent Benefit and Strategic Implications

Analysts noted the treatment benefit was observed consistently across patient subgroups, including those with and without BRCA and other homologous recombination repair (HRR) gene mutations. This is particularly noteworthy for the non-BRCA HRR group, which faces a higher risk of aggressive disease progression. An interim analysis also indicated a promising trend toward improved overall survival.

XTANDI is commercialized in partnership with Astellas Pharma. Until now, TALZENNA has contributed only modest sales since its initial approval in 2018 for a subset of breast cancer patients. One market researcher previously characterized its historical revenue as negligible. The strong TALAPRO-3 data could fundamentally alter that trajectory, supporting Pfizer's strategic effort to expand the drug's label into earlier lines of prostate cancer therapy.

A High-Stakes Development Path

Pfizer's journey with TALZENNA follows a substantial investment. The company acquired the drug for approximately $14 billion. Subsequent efforts to broaden its use in prostate cancer have seen mixed outcomes, including a failed attempt last year to gain approval for patients without HRR gene mutations.

The latest Phase 3 success therefore marks a critical milestone. It could pave the way for regulatory submissions to use the combination in earlier treatment stages for mCSPC.

Forward-Looking Regulatory Strategy

Pfizer stated its immediate plan is to engage with global health authorities to discuss these results and pursue a label expansion. The full dataset is also slated for presentation at upcoming medical congresses.

A successful regulatory outcome would deliver a tangible boost to Pfizer's broader strategy. The company aims to offset upcoming patent expirations for key products by securing expanded clinical indications for existing assets within its portfolio.